Skip to content

BCMA-directed T-cell therapies: Driving Home the Differences Between CARs & Bispecific Antibodies
Tweetorial #1
 *Pre-assessment*

Before you view this Tweetorial, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit. 

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.
1.What are your credentials?(Required.)
2.What is your community of practice?
3.What is your specialty?
4.Based on the MAMMOTH & LocoMMotion study, which of following best characterizes the median OS (in months) of patients w/ multiple myeloma refractory to a proteasome inhibitor, IMiD, & CD38-targeting antibody (triple class refractory)?(Required.)
5.Which of the following points should be included when counseling a patient planning to receive teclistamab?(Required.)
6.71 year old female diagnosed w/ IgG MM w/ t(4;14). She received 4 prior tx including daratumumab, lenalidomide, bortezomib, pomalidomide, carfilzomib & isatuximab. She lives 20 miles from cancer center but does not have a caregiver able to travel to cellular therapy center w/ her. Which treatment is best for her?(Required.)
7.JD is a 56-YOM dx w/ IgM MM w/ t(11;14). He received 5 prior regimens & is considered triple class refractory (but has not had carfilzomib or pomalidomide). He is a schoolteacher w/ the summer off but would like to avoid infusions during the school year.  Which treatment is best?(Required.)
8.Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity) 
Privacy & Cookie Notice